Recently, direct endothelial biopsy has permitted immunohis tochemical and genetic techniques for single cell analyses. 15 However, these approaches have severe limitations with re spect to gaining molecular insights into endothelial biology, Original received July 11, 2012; revision received September 23, 2012; accepted September 28, 2012. In July 2012 Methodological Reviews discuss methods that are of broad interest to the community of cardiovascular investigators and that enable a better understanding of cardiovascular biology, particularly recent technologies in which the methods are still in flux and/or not widely known. It is hoped that these articles, written by recognized experts, will be useful to all investigators, but especially to early-career investigators.
T he endothelium is a delicate monolayer of cells lining the lumen of vessels. Apposed between the circulating blood elements and the vessel wall, it exerts substantial control over the cardiovascular system. The endothelium regulates immune cell entry into the vessels and the sur rounding parenchyma by its expression of adhesion mole cules and chemokines. Vasoactive factors secreted by the endothelium modulate vessel tone and blood flow. The proliferation and migration of vascular smooth muscle cells is also tightly regulated by the endothelium. Thus, the endothelium plays a critical role in vascular homeostasis. Metabolic, hemodynamic, inflammatory, or agerelated de rangements of endothelial function initiate vascular disease, and permit its progression toward cardiovascular morbidity and mortality. Accordingly, there has been intense interest in understanding endothelial biology, ever since the recognition that it was more than a mere cellophane wrapper lining the vessel wall. 1, 2 Studies of human endothelial cell (EC) function in living hu man subjects are limited by the difficulty in directly accessing or imaging the cells. Nevertheless, useful biological and prog nostic information has been obtained by innovative clinical investigators. For example, the endothelium synthesizes va sodilator factors, which are known to be released by increases in shear stress, to induce flowmediated vasodilation. 3, 4 Flow mediated vasodilation can be visualized by ultrasonography or angiography; 5, 6 is impaired by hypercholesterolemia and other metabolic perturbations; 7, 8 and is predictive of cardio vascular morbidity and mortality. 9, 10 Alternatively, one may measure biomarkers of EC function in the circulating blood (such as soluble adhesion molecules, which are increased with vascular inflammation and endothelial activation). Circulating ECs and endothelial progenitor cells (EPCs) may be detected by fluorescent activated cell sorting (FACS). 11, 12 The number of EPCs is reduced in patients with cardiovascular risk factors, and seems to be an independent predictor for mortality. 13, 14 therefore methods for culturing ECs in vitro have been devel oped and refined.
The development of EC culture 30 years ago dramatically accelerated our understanding of endothelial biology. This methodology facilitated molecular insights into the response of the endothelium to hemodynamic and humoral factors, 4, 16 as well as its activation by inflammatory cytokines and lipids. 17, 18 Cell culture studies have revealed important insights into the endothelial regulation of vascular tone and structure, blood fluidity, vascular permeability, and angiogenesis. Recently, the availability of methods to derive ECs from human pluripotent cells has extended the scientific range of human EC studies. One may genetically engineer the parental pluripotent stem cells, that is, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSCs), expand them, and differenti ate them to ECs for in vitro studies (ie, ESCECs or iPSC ECs). Constructs for molecular imaging can be employed to facilitate tracking the cells in vivo. Furthermore, one can also generate patientspecific ECs to study the effects of genetic or epigenetic alterations on endothelial behavior. Ultimately, these cells may be used for therapeutic cell delivery applica tions. This review focuses on the generation of ECs from stem cells, their characterization by genetic, histological and func tional studies, and their possible applications.
EC Culture Methodology
The quality of the science depends on the quality of the cells. Accordingly, one must adhere meticulously to good cell cul ture practice. The details of good cell culture practice are discussed in depth elsewhere, 19 but the general tenets as they apply to EC culture are worthy of brief review.
Authenticity
It is essential to regularly confirm the authenticity, as well as the stability, of the EC lines. ECs should be regularly inter rogated for the expression of characteristic functions, surface markers, and gene expression (described below). Careful re cording of these features, and recording of growth conditions and population doublings, should be used to establish the opti mal passage numbers and growth conditions for experimental protocols.
The derivation of the cells should be known, and their phenotypic and genotypic characteristics confirmed. It is of particular importance in the generation of new EC lines from pluripotent cells that the parental cells be well characterized. For those cells derived from patient materials, one should record key patient characteristics (eg, age, sex, disorders, medications) and the tissue origin of the cells. Furthermore, the methods by which the parental cells were reprogrammed and differentiated to ECs should be recorded in detail.
Standardizing Culture Conditions
The media and other reagents used in the cell culture should be well characterized, and standardized so as to reduce vari ability. However, although serumfree medias are available (eg, Cell Applications, Genlantis) endothelial media usually contains 10% fetal calf serum. Because of lottolot variabili ty and incomplete characterization of serum and other animal products, it is important to evaluate each new batch in parallel with the existing batch. Additionally, commercial endothe lial growth media are typically supplemented with defined growth factors to promote proliferation and maintenance of phenotype (ie, vascular endothelial growth factor [VEGF], basic fibroblast growth factor [bFGF], insulinlike growth factor1) or undefined growth factors derived from bovine neural tissue. The media may also contain other chemical fac tors (eg, ascorbic acid, heparin, hydrocortisone).
Passaging ECs
Even under pristine conditions, cells undergo phenotypic and genotypic changes in culture. Primary cell lines have a limited number of population doublings (usually no >50-60 doublings but often less), a phenomenon known as the Hayflick limit. At the Hayflick limit, cells enter a senescence phase where the cells have lost the ability to divide because their telomeres have shortened to a critical length. However, the signs of senescence are often present before this limit is reached. ECs during senescence will lose their cobblestone morphology and assume a fried egg morphology, replicate more slowly, have greater expression of oxidantsensitive genes such as adhesion molecules and chemokines, and have reduced endothelial function (ie, reduced expression of endothelial NO synthase). 20 The investigator must be familiar with these changes over time, and restrict their studies to ECs in a range of passage numbers (more specifically, population doublings) where the experimental protocol will be unaffected by senescence.
The phenotypic alterations occurring over time in cultured cells are in part because of the artificiality of the culture sys tem. Cells grown on polystyrene (even that coated with a thin layer of matrix proteins) experience a substrate rigidity that is many orders greater than that of tissue (ie, polystyrene has a Young's Modulus of 10 6 kPa, in comparison with physiologi cal soft tissues which are 2-50 kPa). Culturing cells on soft hydrogels, which possess biomimetic physicochemical prop erties has been shown to maintain some phenotypic proper ties, for example, muscle stem cells retain their ability for asymmetric division and replication, and undergo less cell death. 21 Preliminary studies from our laboratory indicate that more tissuelike substrate rigidity can favorably influence the maintenance of endothelial phenotype.
Immortalized cell lines can be subcultured almost indefi nitely. However, such cells are often derived from malignan cies, from viral transformation, from treatment with mutagens, or by genetic modification (eg, with SV40 large T antigen or 22 However, because of their genetic and epigenetic alterations, the behavior of immortalized cell lines may be less representative of cells in vivo, and new scientific insights using these cells should be confirmed with primary cell lines.
Care and Handling of ECs
Standard operating procedures for cell culture should be es tablished. Care should be taken not to expose the cells or tissues to inappropriate conditions (eg, excessive time out of the incubator). The optimal culture temperature and oxy genation should be established. Lower temperatures (<34°C) may slow growth, but higher temperatures (>38°C) may favor apoptosis. Traditionally, EC cultures have been carried out in 95%O 2 /5%CO 2 , but a more appropriate oxygen tension may be in the physiologic range of 5% to 20%. 23 The optimal pH range (≈pH 7.4) for EC culture is narrow.
To obtain single cell suspensions of ECs we have found that the use of TrypLE Express (Invitrogen), a recombinant fungal trypsinlike protease that is temperaturestable, induces less cell death than other approaches.
Cryopreservation permits EC lines to be stored for pro longed periods, but care must be taken during the processes of freezing, storage, and recovery. We have good results when we harvest cells for storage during exponential growth stage, and use 10% v/v DMSO in 10% fetal bovine serum as a cryo protectant. Commercial freezing media contains proprietary components but are designed to increase the recovery of cells upon thawing. Cells should be gradually exposed to the freez ing media to minimize osmotic shock. Upon reconstitution in freezing media, the cells should be cooled at 1° per minute in cell freezing containers stored at −80°C. After 4 to 24 hours, the vials can be transferred to liquid nitrogen. During transfer, care should be taken to avoid exposing the frozen vial to room temperature, as the vial's temperature may change rapidly even within only 1 minute.
The cells should be free of biological contamination (other cells, pathogens such as mycoplasma, or endotoxins). Commercially purchased cells are commonly prescreened for biological contamination, but primary isolated cells are at greater risk for biological contamination. Endotoxin levels can be quantified using a limulus amebocyte lysate colorimetric assay. Myocoplasma levels can be quantified using commer cial kits that detect mycoplasma RNA or DNA. Mycoplasma is a common contaminant. This bacterium from the class of Mollicutes competes with eukaryotic cells for nutrients. Mycoplasma contamination can alter cellular function such as proliferation rates, and NO signaling, and can introduce genetic aberrations. 24 Once mycoplasma is detected, it can be eliminated by treatment of antimycoplasma reagents or an tibiotics. However, it may be more prudent to simply discard the infected cells, and carefully decontaminate the incubator and other equipment that has been in contact with the cells.
Genetic, Histological, and Functional Confirmation of Endothelial Lineage
Immunohistochemical and Genetic Characterization EC Characterization by Immunocytochemistry. To document endothelial lineage, no one immunohistochemical marker is definitive. Rather, one should use a set of endothelial markers, such as plateletendothelial cell adhesion molecule1 (CD31, Figure 1 ), VEcadherin (CD144), endothelial NO synthase, von Willebrand factor, and fetal liver kinase1 (Flk1, also known as kinase insert domain receptor or VEGF receptor 2). Briefly, the cells are fixed with paraformaldehyde (4%), permeabilized with Triton X100 (0.1%), and blocked with either normal goat or donkey serum (1%) for 30 minutes, followed by overnight incubation with the primary antibodies at 4°C. The cells are washed with 1× PBS and incubated with secondary antibodies (ie, Alexa Fluor488 or 594) for 1 hour at room temperature.
Tube-Like Formation
Ac-LDL Nuclei may be stained with Hoechst 33342 dye and the cells examined by fluorescent microscopy. However, because none of the histological markers alone are specific to ECs, functional assays are required to confirm EC lineage.
Functional Assays
ECs Synthesize and Release NO ECs regulate blood flow and blood pressure by releasing the endotheliumderived relaxing factors including NO and prostacyclin. These endotheliumderived factors are critical for maintaining vascular homeostasis. 25 The detection of NO radical in biological samples has been done using a porphyrin electrode, or by spin trapping of NO combined with electron paramagnetic resonance. 26 These are technically difficult because of the short halflife and low concentration of these radicals. The oxidized degradation products, nitrite and nitrate, are stable and can be measured by chemiluminescence after reacting the sample in a reduction chamber to regenerate NO and react it with ozone. 26, 27 However, the most popular and simple method, albeit less sensitive, is to use the fluorimetric Griess reaction assay to measure total nitrates and nitrites. 28, 29 In addition, there are NO fluorescence dye indicators including the 4,5diaminofluorescein dye, but these are not satisfactory because of nonspecific reactions, including with ascorbyl radical in the culture medium. [30] [31] [32] Improved NO probes for intracellular detection are under development, but are not yet commercially available. 33 As an alternative indicator of bioactive NO production, the amount of cGMP, a secondary messenger of NO, may be measured.
EC Activation
ECs are activated by inflammatory cytokines, such as tumor necrosis factorα in vitro, which induces the transcription of cell adhesion molecules (such as intercellular adhesion mol ecule 1) involved in the recruitment of leukocytes. 34, 35 This activation process may also be involved in the homing of highly proliferative EPCs and thus is important in both neo vascularization in regions of ischemia or reendothelialization of areas where the endothelium is impaired. 34, 35 A monocyte EC adhesion assay can be used to quantify EC activation. , and 20 mmol/L HEPES. Human acute monocytic leukemia cell line (THP1) are washed and added to the EC monolayer at a final con centration of 2×10 6 cells/mL. The dish with ECs and mono cytes is placed on a rocking platform and rotated frequently to ensure even distribution of monocytes. After 30 minutes, the medium is removed and ECs are washed with fresh Hanks bal anced salt solution to remove nonadherent monocytes. Cells are fixed (2% glutaraldehyde in Hanks balanced salt solution), stained (CD14 antibody is used to visualize the monocytes), and adherent monocytes are counted by microscopy. 20, 36 Acetylated LDL Uptake by EC Normal ECs can take up acetylated lowdensity lipoprotein (LDL) (Figure 1 ). The uptake of acetylated LDL serves as a commonly used marker for the identification of EC. For acety lated LDL uptake assay, cells are incubated with Dillabeled acetylated LDL (10 µg/mL; Invitrogen) for 4 hours at 37°C.
After incubation, the cells are visualized and photographed under a fluorescence microscope.
Angiogenesis and Vasculogenesis Assays
New blood vessels arise by 2 general mechanisms during development, vasculogenesis, and angiogenesis. Vasculogenesis involves the generation of new vascular networks by incorporation of circulating progenitor cells. Angiogenesis is the formation of new vessels by sprouting from existing vessels. Both angiogenesis and vasculogenesis require EC proliferation and migration. The ability of EC to form tubelike networks in vitro has been employed widely to identify ECs, and to assess vasculogenic and angiogenic potential ( Figure 1) . Notably, other cell types can form networks in Matrigel, but only ECs are capable of forming tubes with lumens. For the in vitro Matrigel assay, cells (2.5×10 5 ) are seeded on 24well plates precoated with growth factorreduced Matrigel and incubated for 24 hours at 37°C to induced tubular network formation. To determine whether these ECs form functional blood vessels in vivo, a Matrigel plug assay is performed using immunodeficient NOD SCID mice, if using human ECs. Matrigel is mixed with bFGF (50 ng/mL) and ECs ( 5×10 5 ). The mixture is subcutaneously injected into the mice. After 14 days, the Matrigel plugs are removed, paraffinembedded, sectioned, and stained with CD31. Capillaries can be quantified using fluorescent microscopy; if human ECs were used, human and mouse specific EC antibodies help to determine the contribution of the human ECs in the Matrigel network.
Furthermore, we also assess the functionality of pluripo tent stem cellderived ECs (ESCECs and iPSCECs) using the mouse hindlimb ischemia model (Figure 2 ). Unilateral hindlimb ischemia is induced by ligating the femoral artery of (4-6 months) male NOD SCID mice. 34, 35 The cells are then delivered, for example, by intramuscular injections into the ischemic limb, and perfusion of the ischemic and nonisch emic hindlimb is assessed over the next 4 weeks using laser Doppler.
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EC Gene Expression Profiles
There is limited information about the gene expression pro files of the ECs derived from stem cells and the native ECs. Li et al 37 compared the gene profiles of human iPSCECs or ESCECs, and human umbilical vein ECs using whole genome microarray. The results suggested that gene expression varia tion of iPSCECs and ESCECs may contribute to biological differences between iPSCECs and ESCECs as compared with human umbilical vein ECs. For iPSCECs, it is impor tant to note that somatic memory does exist [38] [39] [40] which may be useful to explain why iPSCECs have slower growth rate and faster loss of endothelial phenotype than ESCECs or native ECs. Nevertheless, a better understanding of the gene expres sion profiles that guide the development and differentiation of iPSC would facilitate methods to improve the derivation of highfidelity iPSCECs.
Deriving ECs From Pluripotent Stem Cells
Rationale Successful derivation of ECs from human pluripotent stem cells has opened up new opportunities for understanding endothelial biology. Researchers are now able to genetically engineer the parental cells into pluripotent stem cells, expand them, and differentiate them to ECs for in vitro studies. These cells can be tracked during in vivo studies by employing con structs for molecular imaging. Similarly, patientspecific ECs can be generated to study the effects of genetic or epigenetic alterations on endothelial behavior. More importantly, the abil ity to derive large numbers of ECs from parental pluripotential stem cells increases the feasibility of cell therapy applications.
Types of Stem Cells
Stem cells are capable of selfrenewal and directed differentiation. Before the introduction of iPSCs in 2006, 2 broad categories of stem cells had been classified: ESCs and adult stem cells. ESCs are pluripotent stem cells derived from the inner cell mass of the fetal blastocysts. They are able to differentiate into all derivatives of the 3 germ layers: ectoderm, endoderm, and mesoderm. In contrast to ESCs, adult stem cells are already partially committed to a lineage, and can thus produce only a limited number of cell types. For example, hematopoietic stem cells are adult stem cells that are multipotent and can give rise to all types of blood cells but are not able to produce cells of endodermal or ectodermal lineage. However, by comparison to adult differentiated cells, adult stem cells have greater capacity for proliferation and ability to repopulate or repair tissue.
Deriving ECs From ESCs
ESCs are pluripotent cells derived from the inner cell mass of the blastocyst. Human and murine ESCs characteristi cally express pluripotency markers, such as Oct3/4 and Nanog transcriptional factors. However, human and murine ESCs express speciesspecific markers as well. For example, murine ESCs express epithelial cadherin and stagespecific extracellular antigen1, whereas human ESCs express stage specific extracellular antigen3/4 and TRA1-60. Human stem cell lines were first established by Thomson et al. 41 Since then, intensive efforts have been made at methods for directed differentiation and isolation to obtain pure cell populations without contamination of undifferentiated cells, which can give rise to teratomas or tumors consisting of tissue derived from the ectoderm, endoderm, and mesoderm germ layers.
General Considerations of Microenvironmental Conditions
Soluble factors represent the most conventional method to induce endothelial differentiation of pluripotent stem cells. Among the variety of cytokines and growth factors, VEGF seems to play a critical role during the differentiation of ESCs into ECs. VEGF at 50 ng/mL greatly increases the yield of CD31 + cells from mouse ESCderived embryoid bod ies (EBs). 42 VEGF is required for the proliferation of mouse ESCderived VEGF receptor 2 positive progenitor cells. 43 VEGF also dosedependently enhances the formation of EC colonies and plays a critical role in the determination of arte rial and venous fate of the ECs. 43, 44 During the differentiation of Flk1 + sorted cells, high VEGF concentrations can promote upregulation of arterial markers whereas lower concentrations of VEGF induce venous marker expression. 44 Apart from growth factor or cytokinemediated endothe lial differentiation, extracellular matrix plays a key role in angiogenesis and vasculogenesis through supporting adhe sion, migration, proliferation, and survival of ECs. 45 
Murine ESCs to ECs Differentiation
Mouse ESCs spontaneously differentiate into endodermal, mesodermal, and ectodermal lineage on removal of leukemia inhibitory factor from culture. 51 Additionally [52] [53] [54] Thus, the ESC can be directed to differentiate into vascular ECs (ESCderived ECs).
55-57
EB Approach to Generating ECs
We have previously demonstrated that murine ESCs can be differentiated into endothelial lineage by dissociating the ESC colonies into single cells using TrypLE Express and then plat ing the cells onto ultralow adhesion dishes in a differentiation media consisting of α minimum Eagle's media, 10% serum, and βmercaptoethanol. 35 In suspension culture, the murine ESCs form floating aggregates known as EBs. After 4 days of suspension culture, the EBs are then allowed to attach onto 0.2% gelatincoated dishes and cultured for another 10 days in differentiation media. Flk1 is expressed at day 3 of differentia tion whereas latestage endothelial markers VEcadherin and tyrosine kinase receptor 1 are detected after day 5 of differen tiation. 42 Once the EBs are seeded on the 2dimensional tissue culture plates, EC formation can be observed at the borders of the EB colonies. 53 After 3 weeks of differentiation, the murine ESCderived ECs can be purified by FACS using their expres sion of vascular endothelial cadherin (VEcadherin). We pre fer to use VEcadherin rather than CD31 for the purification of murine ECs, because murine ESCs are known to express low levels of plateletEC adhesion molecules (CD31) even in the pluripotent state. 58 
2-Dimensional Culture of murine ESCs to Derive ECs
ECs can be differentiated in the absence of EB formation by using 2dimensional culture systems. Yamashita reported the differentiation of murine ESCs into ECs using VEGF and collagen IVcoated dishes. 47 Murine ESCs were differentiated in differentiation media consisting of αminimum Eagle's medium, fetal bovine serum (10%), and βmercaptoethanol (0.05 mmol/L) on collagen IVcoated dishes for 4 days before purification of Flk1 + and epithelial cadherin mesodermal progenitors. The sorted cells were then grown on collagen IVcoated dishes in differentiation media supplemented by VEGF. Using the same differentiation media, Narazaki et al 59 differentiated murine iPSCs on collagen IVcoated dishes for 4 days before FACS sorting vascular progenitor cells using Flk1 + . Upon purification, the Flk1 + cells were then cultured on collagen IVdishes in differentiation media supplemented with VEGF (100 ng/mL) and 8bromoadenosine3′:5′cyclic monophosphate (8Br cAMP, 0.5 mmol/L) for an additional 3 days before further characterizing for endothelial phenotypic markers. McCloskey et al 60 reported a modification of this procedure in which murine ESCs were first differentiated on collagen IVcoated dishes in the same differentiation media. After 4 days, the cells were purified for Flk1 + expression by FACS and plated onto collagen IV coated dishes in differentiation media supplemented by VEGF for 1 week, producing ECs with cobblestone morphology. However, in our experience, a differentiation period of 3 weeks yielded higher efficiency of ECs when compared with shorter time periods of differentiation.
An important consideration when designing such differen tiation protocol is that cell density seems to influence EC dif ferentiation. For instance, when Flk1 + progenitor cells from mouse ESCs were isolated and plated at a low density, the cells failed to differentiate into ECs. 43 We have also observed that EC differentiation is dependent on the cell density, sug gesting that cell-cell interaction plays an important role in differentiation. On the basis of these findings, a defined cell seeding density of 10 000 cells/cm 2 is used to induce endothe lial differentiation after the selection of Flk1 + progenitor cells from mouse ESCs. 47 
Differentiation to EC in Semisolid Culture or on Stromal Cells
Another differentiation approach involves semisolid culture. Using this method, murine ESCs are cultured in differentia tion media composed of Iscove modified Dulbecco medium, 1% methylcellulose, 15% fetal bovine serum, 2 mmol/l gluta mine, 100 U/mL penicillin G, 100 μg/mL streptomycin, 100 μmol/L monothioglycerol, 1×BSA, insulin and transferrin (BIT). When cultured in this semisolid environment for 11 days, the ESCs can form aggregates that can be directly trans ferred into collagen gels to facilitate sprouting of vascular networks. Furthermore, the aggregates can be dissociated for purification by FACS, or studies by conventional quantitative polymerase chain reaction or immunocytochemical staining.
Coculture of murine ESCs with OP9 stromal cells have also been shown to promote endothelial differentiation. OP9 stromal cells are derived from murine bone marrow. These cells have been immunophenotyped to be positive for anti gens associated with mesenchymal stem cells, such as CD29 and CD44, although being negative in hematopoietic markers CD34 and CD45. 61 When murine ESCs or iPSCs are cocul tured with OP9 in the presence of an angiopoietin1 variant, the pluripotent cells efficiently differentiate into Flk1 + meso dermal precursors.
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Differentiation Efficiencies
The reported efficiency of differentiation protocols varies con siderably. However, it is difficult to compare the efficiencies of the various differentiation protocols because of the fact that dif ferent starting cells and markers are employed at different time points using different technologies. That being said, the report ed efficiencies for yielding ECs with the EB formation method are 16% in murine ESCs, 35 and range from 10% to 50% in hu man ESCs. 34, 63, 64 The OP9 coculture method yields 35% ECs from murine ESCs, 62 7 to 13% from human ESCs, 65, 66 and 16% from human iPSCs. 66 The collagen IV method yielded 15% to 39% in murine ESCs, 47, 59 and 14% in murine iPSCECs.
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Characterization of ESC-Derived ECs
These ESCderived ECs (ESCECs) are validated to be of EC lin eage based on the multiple surface markers, gene expression, and functional studies as described earlier. 42 Subsequently, the cells can be further characterized in vivo, by their ability to incorpo rate into the vasculature of the ischemic limb or myocardium. [67] [68] [69] We tracked the fate and function of transplanted ESCECs in the ischemic murine myocardium. 35, 70 Murine ESCs were first transduced with a construct that encoded luciferase (for biolumi nescence imaging) and red fluorescent protein (for histological tracking). After the ESCs differentiated into ECs, the ESCECs or vehicle were injected into the ischemic area of the left ventri cle after ligation of the left anterior descending coronary artery. Bioluminescence imaging showed that the ESCECs survived to 8 weeks, and echocardiography revealed improved systolic function in the hearts injected with ESCECs. Histological stud ies revealed increased myocardial capillary density in the hearts treated with cell therapy. Additionally, we have shown the ESC ECs engraft into ischemic hindlimbs (a murine model for periph eral artery disease, Figure 2 ) and restore perfusion in the leg. 35 These studies suggest that ESCEC may have a therapeutic effect in the treatment of ischemic vascular diseases.
Human ESCs to ECs Differentiation
Human ESCs exhibit a number of differences from murine ESCs, such as their independence from leukemia inhibitory factor and dependency on bFGF for maintenance of selfre newal. However, Levenberg et al 71 reported that human ESCs can be differentiated spontaneously through EB formation in the absence of bFGF. After 10 to 15 days of differentia tion, these human EBs gave rise to various lineages includ ing CD31 + ECs. When the CD31 + cells were purified from the EBs by FACS, ≈80% purity as achieved. 71 As a modification of this protocol, human ESCs were grown in suspension as EBs in the presence of Iscove's modified Dulbecco's medium, 20% defined fetal bovine serum and 450 mmol/l monothio glycerol. 63 After 4 days, the EBs were reattached to gelatin coated dishes in the presence of EC growth medium2 that contained numerous growth factors including VEGF and epi dermal growth factor. After 12 days of differentiation, the EB outgrowths were FACS purified based on CD31 expression. This method yielded 12% CD31 + cells, and on expansion and repurification, the cells were 97% CD31 + . Using a more directed approach mimicking the growth fac tor induction signals during cardiovascular development, Yang et al 64 demonstrated a stepwise differentiation protocol yield ing endothelial, cardiac, and smooth muscle lineages from the same precursor stem cell. The human ESCs were differentiated in the presence of bone morphogenetic protein 4 on day 0; bone morphogenetic protein 4, bFGF, and activin during days 1 to 4; Wnt inhibitor Dickkopfrelated protein 1 (DKK1) and VEGF from days 4 to 8, and VEGF, DKK1, and bFGF thereafter.
The derivation of ECs from human ESCs via different culture conditions include human ESC induced EB formation grown on gelatincoated plates, 34 ,64,71-74 human ESC grown on bone marrow stromal OP9 coculture, 65, 66, 75 human ESC grown on collagen IV coated plates, 76 and human ESCinduced EBs grown on methylcellulose. 77 Although the differentiation of human ESCs to ECs have been achieved using a variety of differentiation protocols, methodologies involving cytokines/ growth factors and extracellular matrix environments need to be further explored and refined.
iPSCs as a Source for ECs
Generation of iPSC
In 2006, Yamanaka and colleagues 78 demonstrated that mouse fibroblasts could be reprogrammed to iPSCs by introduction of 4 transcriptional factors including octamerbinding tran scription factor3/4, SRYrelated highmobilitygroupbox protein2, Krüppellike factor 4, and cMyc. 78, 79 The induced expression of these 4 transcriptional factors activates a net work of genes required for pluripotency, and gradually trans forms the somatic cells into pluripotential stem cells. These cells exhibit similar morphological and growth patterns com pared with ESCs and they have the potential to differentiate into lineages of the 3 germ layers. [80] [81] [82] [83] In 2007, Thomson et al 84 used octamerbinding transcription factor3/4 and SRYrelated highmobilitygroupbox protein2 together with Nanog and Lin28 as reprogramming factors to generate iPSCs. The de velopment of iPSCs has opened a new avenue for cardiac and vascular regeneration, as well as the opportunity to understand the differentiation of ECs from pluripotent stem cells.
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Differentiating iPSCs to ECs iPSCs are capable of differentiating into all cardiovascular cells including ECs, vascular mural cells, smooth muscle cells, 87 and cardiomyocytes. 55, 59 Generally, approaches for differentiation of human or murine ESCs can be also applied in the differentia tion of human iPSCs (Figure 3) . We differentiate human iPSCs after dissociating the colonies (with type IV collagenase for 10 minutes) and then transferring iPSCs to ultralow attachment dishes containing differentiation media for 4 days to form EBs. The differentiation media consisted of αminimum Eagle's medium, fetal bovine serum (20%), βmercaptoethanol (0.05 mmol/L), nonessential amino acids (1%), bone morphogenetic protein 4 (50 ng/mL), and VEGFA. The 4day EBs were then seeded on 0.2% gelatincoated dishes and cultured for another 10 days in differentiation media in the absence of bone mor phogenetic protein 4. Differentiation media was changed every 2 days. To purify the pluripotent stem cellderived ECs, single cell suspensions were obtained using accutase for 20 minutes at 37°C to dissociate differentiated cells, which were then washed with 1× PBS containing 5% BSA, passed through a 70µm cell strainer, and incubated with phycoerythrin (PE) conjugated antihuman CD31 antibody and antiVEcadherin antibody for 30 minutes. Isotypematched antibody served as negative control and 1% propidium iodide was used to stain the nonviable cells. Then FACS purified ECs were expanded in EGM2MV. Currently, our methodology yields 10 to 20% VE cadherin + /CD31 + cells, which can be purified to 75% to 90% with a second FACS.
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Direct Reprogramming as a Source for ECs
The ability to generate iPSCs has already had practical applications in the development of diseasespecific cells for October 26, 2012 understanding mechanisms of disease, and in the production of iPSCderived cell lines for drug screening. Although there is promise for the application of iPSCderived cells for therapy, there are major limitations, including the risk of teratoma, the difficulty in differentiating highfidelity therapeutic cells, and the prolonged process which currently takes months. Direct reprogramming, from one somatic cell type to another desired somatic cell type, is thus an attractive alternative approach. For example, fibroblasts have been converted to neurons, 88 and to cardiomyocytes. 89 Typically, a handful of genes, known to be involved in development of the desired cell type, are overexpressed in the fibroblast for transdifferentiation. A recent article by Margariti et al 90 converted fibroblasts to ECs using the Yamanaka factors and culture conditions favoring EC growth.
Heterogeneity of the ECs Derived From Nuclear Reprogramming
There is heterogeneity of endothelial structure and function in vivo, that is not generally appreciated, nor fully maintained in cell culture. In vivo, the phenotype of the EC is influenced by the developmental program (eg, lymphatic, venous, or arte rial), the surrounding parenchyma and its metabolic activity (eg, the elaboration of angiogenic cytokines by tumor cells), as well as hemodynamic and humoral factors. Endothelial heterogeneity is necessary to support specialized tissue func tion. For example, the endothelium of the cerebral microvas culature forms tight cell junctions and is far less permeable than the lymphatic endothelium which is fenestrated. In the former case, the endothelium protects the brain from shifts in interstitial fluid that could adversely effect intracranial pres sure, whereas in the latter case, the increased permeability of the lymphatic endothelium subserves transport of interstitial protein back to the systemic circulation. One manifestation of endothelial heterogeneity is the elaboration of different surface proteins, that have been termed vascular zip codes. The remark able heterogeneity of endothelial surface markers have been well demonstrated by phage display studies. 91 The functional relevance of this heterogeneity is illustrated by the expression of specific adhesion molecules that facilitate monocyte entry at sites of disturbed flow in the aorta, whereas different adhesion molecules regulate the trafficking of immune cells through the venous endothelium of the lymph nodes. 92, 93 The meticulous investigator is cognizant of endothelial heterogeneity. At the very least, one should confirm by im munohistochemistry or FACS that the ECs one is using ex perimentally are of venous (Ephrin B), arterial (Ephrin B2), or lymphatic (podoplanin or Lyve 1) subtype. We have found that our iPSCderived ECs are heterogenous, with all 3 sub types represented. Furthermore, the culture conditions can influence the percentage of each subtype. Higher doses of VEGFA (50 ng/mL) and 8BrcAMP in the differentiation medium increase the prevalence of the arterial phenotype, for example (unpublished results). One should be aware that in the absence of their normal milieu, ECs may lose some of their in vivo characteristics, or acquire new properties, which could affect experimental results, and the relevance of the cell culture model.
MiRNAs and Endothelial Lineage
Recent work has highlighted the role of miRNA (miR) in regulation of EC development and phenotype. Pivotal stud ies by Yang et al 94 showed that knockdown of miRNA pro cessing enzyme, Dicer, disrupted angiogenesis. Since then, a score of miRs has been identified to modulate EC genes in cluding miR126, miR19a, and miR21. 95, 96 However, little is known about the role of miRNA in the EC differentiation. In a recent article, Kane et al 97 found that overexpression of miR99b, 181a, and 181b levels increased the expression of EC markers and function. In addition, long noncoding RNA regulates vascular development. Alterations in the ratio of tie 1 mRNA to the tie1 antisense long noncoding RNA, has been implicated in human vascular anomalies. 98 It is likely that with a greater understanding of the regulation of their roles in endothelial development, miRNA and long noncoding RNA may be manipulated for the purpose of EC differentiation or directed reprogramming.
Potential Therapeutic Applications of EC Derivation
Modeling Vascular Disease An immediate application of iPSC technology is to derive vas cular cells from patients with vascular diseases. In particular, one would focus on vascular diseases that are believed to have a strong genetic component; the pathophysiology of which is not well understood; and do not have good animal models. Fibroblasts may be harvested from a patient with such a vas cular disease. The fibroblasts can be induced to the pluripo tential state using reprogramming factors, and then induced to form endothelial or vascular smooth muscle cells. Once their vascular phenotype has been confirmed by the characteriza tion studies described above, the iPSCderived vascular cell may be further studied to characterize abnormal cell functions (Figure 3 ). For example, patientspecific iPSCderived cardio myocytes recapitulated the morphological and functional phe notypes for familial dilated cardiomyopathy and these cells may serve as a useful model to explore disease mechanisms and therapeutics. 99 Similarly, once the diseaseinadish model is created, and the model is shown to faithfully recapitulate the vascular disease of the patient, then it may also be a useful tool for drug or small molecule screening for vascular disease. Such an approach may uncover therapeutic avenues that may merit further development.
ECs in Engineered Blood Vessels
Vascular regeneration refers to the restoration of normal vascular function and structure, the reversal of vascular senescence, and the development of vascular networks. ECs are essential components in vascular regeneration, and in many different tissue engineering applications such as vascular grafts. Vascular tissue engineering may involve the in vitro engineering of biological conduits for revascularization of various tissues (Figure 3 ). An early report described a vascular graft made with ECs, vascular smooth muscle cells, fibroblast, and collagen gel medium on a Dacron mesh. 100 Since then, a variety of tissueengineered grafts have used different scaffolds to enhance cell viability, maintain vascular phenotype, and provide for the mechanical strength to withstand hemodynamic forces. Vascular cells can be seeded to various materials including collagen, 100 biodegradable scaffolds, 101 or vessels made of decellularized matrices. 102 ECs and SMCs may be obtained from the patient's own vein segments, then cultured in vitro to get sufficient cell number for a graft. The ECs can form a barrier layer and are able to secrete von Willebrand factor and prostacyclin in in vitro condition.
The major disadvantages of using adult cells from blood vessels are their limited proliferation capacity and suscepti bility to cellular senescence. 103 Furthermore, patientspecific deficiencies of endothelial function, or even tissuespecific differences in endothelial function, may reduce the applicabil ity of autologous adult ECs. 104 However, the use of stem or progenitor cells to derive ECs may surmount these difficulties.
Socalled EPCs may be isolated from the patient's blood or bone marrow (using FACS and surface markers such as CD34, Flk1, and VEGF receptor 2), and expanded in ex vivo culture. 11, 12 Parenthetically, the widely used term EPC is a misnomer. The surface markers that are commonly used for identification of human EPCs include markers that are not specific for endothelial lineage, such as CD133 and kinase insert domain receptor. 12 In addition, methods for harvesting, purifying, and culturing EPCs are not standardized. Thus, se mantic confusion is compounded by methodological variation. Casual readers of the literature may not recognize that EPCs are a mixed population of progenitor cells of different lineag es. Within this population of cells, there are true endothelial progenitors that can incorporate into the vascular network, whereas hematopoietic progenitors may contribute by secret ing angiogenic cytokines. In cell culture, EPCs may form earlyoutgrowth and lateoutgrowth colonies. Cells derived from the former colonies are clearly not of endothelial origin, expressing markers of hematopoietic lineage, and are morpho logically distinct from lateoutgrowth cells, which grow in a cobblestone pattern reminiscent of ECs. At present, there are no surface markers that clearly distinguish early endothelial progenitors; the best approach currently is to define endothe lial lineage morphologically (ie, with tubulogenesis assays). The formation of a tubular network in Matrigel is a defining feature of endothelial progenitors, which can also incorporate into existing tubular networks formed by differentiated ECs. Kaushal and colleagues demonstrated that EPCseeded de cellularized porcine iliac arteries implanted into sheep were structurally, functionally, and morphologically similar to a na tive vessel with a high flow patency. 105 EPCs have also been grown on a decellularized vessel, and successfully transplant ed in an interposition graft in the carotid artery. 106 However, this approach may generate an endothelial monolayer with some differences from in vivo ECs, with lower expressions of NO synthase, prostacyclin, and tissue plasminogen activa tor. 107 It should be noted also that EPC decrease in number with aging, which might complicate the use of these cells for clinical conditions. 108 Pluripotent stem cellderived ECs may have several advan tages over ECs from patient vein segments or EPCs, includ ing that they can potentially generate larger quantities of ECs. In one study, mouse ESCs were added to a microporous tube made of polyurethane, and differentiated into ECs and SMCs in vitro. 109 ECs may also be genetically engineered, for ex ample, to reduce senescence. ECs derived from mouse ESCs were transduced with human telomerase reverse transcriptase to immortalize the ECs. 110 These genetically modified ECs were used to endothelialize hybrid grafts made of a SMC layer on polyglycolic acid scaffolds which were then subcutaneous ly implanted into hairless SCID (nude) mice. A typical blood vessel structure with EClining and a vessel wall composed of SMC and collagen was generated using this approach. October 26, 2012
ECs for Generating the Microvasculature ECs have the ability to form capillarylike networks in vi tro. [111] [112] [113] Human umbilical vein ECs, keratinocytes, and fi broblasts were seeded together in a collagen sponge to form spontaneous capillarylike structures in vitro, followed by implantation in mice. 114 The capillarylike tubes formed within the engineered skin tissue connected with the host vessels within 4 days of implantation. To produce larger and more complex tissue constructs, homogeneous distribution of microvessels throughout the tissue needs to be achieved for transport of nutrients and oxygen. 115 Also, grafts seeded with CD34 + bone marrow derived EPCs showed significant ly improved endothelialization and increased microvessels within the neointima when these grafts were implanted into the thoracic aortae of adult dogs. [116] [117] [118] In human, vascular re generation has been attempted with autologous BMNCs or granulocyte colonystimulating factor-expanded peripheral blood mononuclear cells in patients with coronary as well as peripheral arterial disease. Phase I and II trials have been completed in patients with acute myocardial infarction, 119 as well as in subjects with chronic ischemic heart disease. [120] [121] [122] Thus far, the majority of these early trials have suggested that modest improvements may be gained in some cardiac end points such as global and regional contractility with little risk for these cellbased therapies. 119 Additionally, since the first study in 2002 there have been at least 30 reported therapeutic cell trials in patients with peripheral arterial disease, some of which have shown promise in improving perfusion, healing ulcers, and increasing walking distance. 123, 124 However, most of these trials have been small observational studies, and need confirmation in larger randomized clinical trials (Figure 3 ).
Concluding Remarks
One is only as old as one's endothelium. 125 Cardiovascular health begins with restoration of endothelial homeostasis. Accordingly, studies of endothelial biology will continue to lead to new insights of clinical relevance and therapeutic promise. The generation of diseasespecific iPSCderived vascular cells provides an opportunity to delve deeper into the mechanisms of disease. Such cells can be used to understand the early events in the pathogenesis of diseases that are now only recognized in their late stages. Furthermore, adult and pluripotential stem cells are under investigation to determine their utility for ischemic syndromes affecting the coronary and peripheral circulations. Although it remains to be seen whether adult stem cells promote vascular regeneration and relieve ischemic syndromes, early studies have been promising, albeit the effect sizes modest. Because they have greater proliferative capacity, pluripotential stem cells seem to hold greater promise for the future of vascular regeneration. The fidelity and safety of iPSC/ESCderived ECs needs to be confirmed before clinical trials. Furthermore, methods for their derivation need to be improved. Still to be determined are important clinical issues, such as dosing, duration, and methods of delivery of therapeutic cells. Under development are bioengineering solutions, in which the cells are administered within a decellularized or synthetic matrix. These exciting developments in translational endothelial biology will open new vistas for exploration and novel therapeutic avenues for development.
